In the world of oncology, advancements go beyond the development of new drugs. True innovation in cancer care involves collaborative efforts to eliminate barriers to treatment access. Experts at the Institute for Value-Based Medicine session in Arlington, Virginia, emphasized the importance of strategic partnerships between oncologists and pharmacists in addressing operational and policy obstacles that hinder equitable access to essential therapies and diagnostic tests.
Pharmacists play a crucial role in multidisciplinary oncology care teams as the field transitions towards value-based delivery. By optimizing outpatient delivery models, pharmacy departments are working to make advanced treatments like bispecific antibodies and CAR T-cell therapy more accessible, with a focus on cost reduction. Strategies for integrating toxicity management across inpatient and outpatient settings are vital, especially for therapies like CAR T-cell therapy that require close monitoring for adverse effects like CRS and ICANS.
In lung cancer care, efforts are being made to enhance early diagnosis and expand access to biomarker testing, which can impact eligibility for immunotherapy. Payers are urged to recognize the value of personalized treatments to avoid unnecessary harm to patients. Discussions also revolve around evolving immunotherapy strategies, such as treatment duration and decision-making processes in the face of immune-related adverse events. The goal is to address financial and systemic barriers that contribute to disparities in accessing biomarker testing and advanced therapies.
In the realm of malignant hematology, equitable access to innovative care faces numerous challenges, from clinical hurdles to policy-level obstacles. Experts underscore the importance of partnerships, outpatient treatment models, and payer reforms in ensuring all patients can benefit from advancements in the field. Targeted investments in regulatory reform, collaborative trial networks, and real-world evidence generation are deemed necessary to bridge the gap between scientific discoveries and clinical implementation.
A critical discussion on cancer care equity highlighted the need for multidisciplinary efforts to improve prevention, diagnosis, and treatment. Challenges such as financial toxicity and complex pricing structures that limit access to affordable care were addressed. The conversation also shed light on structural challenges in healthcare systems in the US and Canada, emphasizing the need for reforms to ensure equitable access to cancer care for all patients.
- Collaborative efforts between oncologists and pharmacists are essential for optimizing cancer care delivery and improving patient outcomes.
- Addressing financial and systemic barriers is crucial to ensure equitable access to advanced therapies in oncology.
- Payers play a vital role in recognizing the value of personalized treatments and supporting early diagnosis initiatives in cancer care.
- Strategic investments in regulatory reform and real-world evidence generation are necessary to bridge the gap between scientific advancements and clinical practice.
Tags: immunotherapy, regulatory
Read more on ajmc.com